Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6.

Drug Des Devel Ther · 2022 · PMC9553160 · PMID 36238196

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Although there was no significant difference in hepatic TC between T2DM+NAFLD group and Semaglutide group, a decreasing trend still occurred in Semaglutide group ( Figure 2B and Supplementary Table 3 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.